Atomic AI founder and CEO Raphael Townshend discusses the company’s work deriving three-dimensional structures of RNA molecules. He also describes its AI-driven drug-discovery platform.
Atomic AI develops ATOM-1, a platform for RNA structure prediction. The article covers the company's founding and its $35 million Series A led by Playground Global.
Atomic AI launched with a $35 million Series A led by Playground Global, bringing its total raise to $42 million. Founder and CEO Raphael Townshend says the company is building RNA-targeted molecules through an approach combining machine learning and in-house wet-lab biology.
Atomic AI raises a $35 million Series A led by Playground Global to advance RNA-focused drug discovery. The company plans to combine artificial intelligence with structural biology to unlock RNA as a drug-discovery target, which it sees as a new frontier for drug discovery.
